Literature DB >> 11830666

The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness.

Alison A Humbles1, Bao Lu, Daniel S Friend, Shoji Okinaga, Jose Lora, Amal Al-Garawi, Thomas R Martin, Norma P Gerard, Craig Gerard.   

Abstract

CCR3 is a chemokine receptor initially thought specific to eosinophils but subsequently identified on TH2 cell subsets, basophils, mast cells, neural tissue, and some epithelia. Because of the prominent role of these cells in allergic disease, including asthma, we generated mice deficient in CCR3 to determine its contribution in a model of allergic airway disease. Here we show that CCR3 is important for the basal trafficking of eosinophils to the intestinal mucosa but not the lung. In contrast, CCR3 disruption significantly curtails eosinophil recruitment to the lung after allergen challenge, with the majority of the eosinophils being arrested in the subendothelial space. Further, a role for CCR3 in mast cell homing has been identified; after sensitization and allergen challenge, we find increased numbers of intraepithelial mast cells in the trachea of knockout mice. Physiologically, we find that the net result of these complex cell fates after sensitization and allergen challenge is a paradoxical increase in airway responsiveness to cholinergic stimulation. These data underscore a more complex role for CCR3 in allergic disease than was anticipated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11830666      PMCID: PMC122216          DOI: 10.1073/pnas.261462598

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Th1- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts.

Authors:  L M Teran; M Mochizuki; J Bartels; E L Valencia; T Nakajima; K Hirai; J M Schröder
Journal:  Am J Respir Cell Mol Biol       Date:  1999-04       Impact factor: 6.914

2.  Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses.

Authors:  A Minty; P Chalon; J M Derocq; X Dumont; J C Guillemot; M Kaghad; C Labit; P Leplatois; P Liauzun; B Miloux
Journal:  Nature       Date:  1993-03-18       Impact factor: 49.962

3.  CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy.

Authors:  C J Corrigan; A Haczku; V Gemou-Engesaeth; S Doi; Y Kikuchi; K Takatsu; S R Durham; A B Kay
Journal:  Am Rev Respir Dis       Date:  1993-03

4.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma.

Authors:  D S Robinson; Q Hamid; S Ying; A Tsicopoulos; J Barkans; A M Bentley; C Corrigan; S R Durham; A B Kay
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

5.  Mouse Eotaxin expression parallels eosinophil accumulation during lung allergic inflammation but it is not restricted to a Th2-type response.

Authors:  J A Ganzalo; G Q Jia; V Aguirre; D Friend; A J Coyle; N A Jenkins; G S Lin; H Katz; A Lichtman; N Copeland; M Kopf; J C Gutierrez-Ramos
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

6.  Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils.

Authors:  P D Ponath; S Qin; D J Ringler; I Clark-Lewis; J Wang; N Kassam; H Smith; X Shi; J A Gonzalo; W Newman; J C Gutierrez-Ramos; C R Mackay
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

7.  Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation.

Authors:  P J Jose; D A Griffiths-Johnson; P D Collins; D T Walsh; R Moqbel; N F Totty; O Truong; J J Hsuan; T J Williams
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

8.  Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity.

Authors:  D B Corry; H G Folkesson; M L Warnock; D J Erle; M A Matthay; J P Wiener-Kronish; R M Locksley
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

9.  Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.

Authors:  P S Foster; S P Hogan; A J Ramsay; K I Matthaei; I G Young
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

10.  Cloning, expression, and characterization of the human eosinophil eotaxin receptor.

Authors:  B L Daugherty; S J Siciliano; J A DeMartino; L Malkowitz; A Sirotina; M S Springer
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

View more
  109 in total

1.  Autoimmunity to neuroretina in the concurrent absence of IFN-γ and IL-17A is mediated by a GM-CSF-driven eosinophilic inflammation.

Authors:  So Jin Bing; Phyllis B Silver; Yingyos Jittayasothorn; Mary J Mattapallil; Chi-Chao Chan; Reiko Horai; Rachel R Caspi
Journal:  J Autoimmun       Date:  2020-06-24       Impact factor: 7.094

Review 2.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

3.  CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung.

Authors:  Cyrille Mionnet; Vanessa Buatois; Akira Kanda; Valerie Milcent; Sebastien Fleury; David Lair; Marie Langelot; Yannick Lacoeuille; Edith Hessel; Robert Coffman; Antoine Magnan; David Dombrowicz; Nicolas Glaichenhaus; Valerie Julia
Journal:  Nat Med       Date:  2010-10-31       Impact factor: 53.440

4.  Deficiency of CXCR2, but not other chemokine receptors, attenuates autoantibody-mediated arthritis in a murine model.

Authors:  Jonathan P Jacobs; Adriana Ortiz-Lopez; James J Campbell; Craig J Gerard; Diane Mathis; Christophe Benoist
Journal:  Arthritis Rheum       Date:  2010-07

5.  Temporal production of CCL28 corresponds to eosinophil accumulation and airway hyperreactivity in allergic airway inflammation.

Authors:  Alison E John; Molly S Thomas; Aaron A Berlin; Nicholas W Lukacs
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

Review 6.  The future of asthma therapy: integrating clinical and experimental studies.

Authors:  David B Corry; Farrah Kheradmand
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 7.  Biology of the eosinophil.

Authors:  Carine Blanchard; Marc E Rothenberg
Journal:  Adv Immunol       Date:  2009       Impact factor: 3.543

Review 8.  Chemotactic factors associated with eosinophilic gastrointestinal diseases.

Authors:  Carine Blanchard; Marc E Rothenberg
Journal:  Immunol Allergy Clin North Am       Date:  2009-02       Impact factor: 3.479

9.  Ablation of type I hypersensitivity in experimental allergic conjunctivitis by eotaxin-1/CCR3 blockade.

Authors:  Dai Miyazaki; Takao Nakamura; Masaharu Ohbayashi; Chuan Hui Kuo; Naoki Komatsu; Keiko Yakura; Takeshi Tominaga; Yoshitsugu Inoue; Hidemitsu Higashi; Meguru Murata; Shuzo Takeda; Atsuki Fukushima; Fu-Tong Liu; Marc E Rothenberg; Santa Jeremy Ono
Journal:  Int Immunol       Date:  2009-01-15       Impact factor: 4.823

Review 10.  Regulation of G-protein-coupled signaling pathways in allergic inflammation.

Authors:  Kirk M Druey
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.